Premium
Could inhibition of metalloproteinases be used to block the process of metastasis?
Author(s) -
Alba Jesús,
Barcia Ramiro,
GutiérrezBerzal Javier,
RamosMartínez Juan I.
Publication year - 2022
Publication title -
cell biochemistry and function
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.933
H-Index - 61
eISSN - 1099-0844
pISSN - 0263-6484
DOI - 10.1002/cbf.3730
Subject(s) - matrix metalloproteinase , metastasis , extracellular matrix , proteases , cancer research , primary tumor , stroma , mesenchymal stem cell , circulating tumor cell , cancer cell , microbiology and biotechnology , cancer , biology , pathology , chemistry , medicine , enzyme , biochemistry , immunohistochemistry , genetics
Metastasis is a multisequential process that allows tumor cells to migrate to tissues distant from the primary tumor. Only a small number of cells escape from the primary tumor; however, the metastases generated are responsible for more than 90% of cancer deaths. Many metastatic processes initially require the total or partial start‐up of a program for the transformation of tumor epithelial cells into mesenchymal cells (EMT). The launching of the EMT program is stimulated by cytokines and other elements produced by the diverse types of cells composing the tumor stroma. In parallel, a process of destabilization of the extracellular matrix (ECM) takes place by means of the synthesis of proteases of the matrix metalloproteinases (MMPs) family. EMC degradation allows the exportation of some tumor cells as mesenchymal cells to the circulatory system and their subsequent implantation in a tissue distant from the primary tumor. The blocking of these both processes appears as a hypothetical stop point in the metastatic mechanism. The present review deals with the different options to achieve the inhibition of MMPs, focusing on MMP7 as a target given its involvement in the metastatic processes of a wide variety of tumors.